MilliporeSigma

[Necrotizing gastritis in a patient in severe neutropenia].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego (2015-02-27)
Konrad Pielaciński, Ewa Lech-Marańda, Krzysztof Warzocha, Marek Dedecjus, Monika Prochorec-Sobieszek, Andrzej B Szczepanik
ABSTRACT

One extremely rare complication of chemotherapy for hematologic malignancies that is burdened with a high mortality rate (50%-80%) is necrotizing gastritis and gastric gangrene as result of poor clinical outcome of neutropenic gastritis (NG). We present a unique case of a neutropenic patient with necrotizing full thickness gastritis due to bacterial and fungal infection. Up to date only few such cases have been reported in world literature. A 28-year-old patient was subjected to dose-escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone), (chemotherapy regimen) for Hodgkin lymphoma. In neutropenic patient abdominal pain, bleeding from the alimentary tract was observed. Hemorrhagic gastritis was recognized at endoscopy and CT demonstrated marked gastric wall thickness. Following NG diagnosis intensive treatment was initiated. On day 2 the patient's condition deteriorated (septic shock, multiple organ failure). Repeat endoscopy revealed gastric necrosis and laparotomy was performed. As consequence of cardiac arrest and cardiopulmonary resuscitation the surgical procedure was limited to total gastrectomy, feeding jejustomy and esophageal drainage through nasoesophageal catherization. Roux-loop esophagojejunostomy was performed on day 22 and supplemented 4 days later by endoscopic placement of covered self-expandable stent due to anastomosis leak. The procedure proved successful and oral feeding was well-tolerated. The patient was discharged in 32 days following recognition of gastric necrosis. Chemotherapy complications in neutropenic patients are life-threatening conditions. Immediate pharmacological treatment usually leads to improvement. Surgical management usually the resection of necrotic zones is restricted to cases of poor prognosis or deterioration of patient's condition and complications.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, 1.5-2.0 units/mg solid, BioReagent, suitable for cell culture
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, crystalline, 1.5-2.0 U/mg
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, for fluorescence, mixture of bleomycin sulfate salts, lyophilized, powder or crystals, white to off-white
Sigma-Aldrich
Bleomycin sulfate from Streptomyces verticillus, BioXtra, crystalline
Sigma-Aldrich
Vincristine sulfate salt, 95.0-105.0% (HPLC), powder or crystals
Sigma-Aldrich
Etoposide, synthetic, 95.0-105.0%, powder
Etoposide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Procarbazine hydrochloride, ≥98% (HPLC)
Doxorubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
USP
Prednisone, United States Pharmacopeia (USP) Reference Standard
Supelco
Prednisone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Doxorubicin hydrochloride, suitable for fluorescence, 98.0-102.0% (HPLC)
Sigma-Aldrich
Vincristine sulfate, meets USP testing specifications
Sigma-Aldrich
Doxorubicin hydrochloride, 98.0-102.0% (HPLC)
Sigma-Aldrich
Prednisone, ≥98%
USP
Doxorubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Vincristine sulfate, European Pharmacopoeia (EP) Reference Standard
Bleomycin sulfate, European Pharmacopoeia (EP) Reference Standard
Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard